JP2014512369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512369A5 JP2014512369A5 JP2014505179A JP2014505179A JP2014512369A5 JP 2014512369 A5 JP2014512369 A5 JP 2014512369A5 JP 2014505179 A JP2014505179 A JP 2014505179A JP 2014505179 A JP2014505179 A JP 2014505179A JP 2014512369 A5 JP2014512369 A5 JP 2014512369A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- gdnf variant
- human gdnf
- human
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474024P | 2011-04-11 | 2011-04-11 | |
| US61/474,024 | 2011-04-11 | ||
| PCT/US2012/031927 WO2012141936A1 (en) | 2011-04-11 | 2012-04-03 | Variants of human gdnf |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512369A JP2014512369A (ja) | 2014-05-22 |
| JP2014512369A5 true JP2014512369A5 (cg-RX-API-DMAC7.html) | 2015-04-23 |
| JP6093345B2 JP6093345B2 (ja) | 2017-03-08 |
Family
ID=45932578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505179A Active JP6093345B2 (ja) | 2011-04-11 | 2012-04-03 | ヒトｇｄｎｆの変異体 |
Country Status (28)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190142868A1 (en) | 2016-05-13 | 2019-05-16 | Instituto de Medicina Moleccular | Methods of treating diseases associated with ilc3 cells |
| US20230022970A1 (en) * | 2019-12-19 | 2023-01-26 | Transfert Plus, Société En Commandite | Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies |
| JP2024522938A (ja) | 2021-06-03 | 2024-06-21 | フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド | 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2119463C (en) | 1991-09-20 | 2003-09-16 | Leu-Fen H. Lin | Glial cell line-derived neutrophic factor |
| US6184200B1 (en) * | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
| US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| DE19816186A1 (de) | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
| US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
| FI20070808A0 (fi) | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
| CN101775072B (zh) | 2008-05-21 | 2012-09-05 | 王尚武 | 一种融合穿透肽的神经细胞营养因子gdnf |
| ES2545614T3 (es) * | 2009-02-06 | 2015-09-14 | Pepscan Systems Bv | Proteínas truncadas con nudo de cistina |
-
2012
- 2012-03-04 UA UAA201311714A patent/UA112981C2/uk unknown
- 2012-03-27 TW TW101110653A patent/TWI583698B/zh active
- 2012-04-03 US US14/000,704 patent/US9243046B2/en active Active
- 2012-04-03 CN CN201280018010.7A patent/CN103635201B/zh active Active
- 2012-04-03 CA CA2833158A patent/CA2833158C/en not_active Expired - Fee Related
- 2012-04-03 EP EP12712874.2A patent/EP2696889B1/en active Active
- 2012-04-03 NO NO12712874A patent/NO2696889T3/no unknown
- 2012-04-03 HU HUE12712874A patent/HUE036239T2/hu unknown
- 2012-04-03 JP JP2014505179A patent/JP6093345B2/ja active Active
- 2012-04-03 WO PCT/US2012/031927 patent/WO2012141936A1/en not_active Ceased
- 2012-04-03 EA EA201370204A patent/EA025129B1/ru not_active IP Right Cessation
- 2012-04-03 MX MX2013011919A patent/MX337206B/es active IP Right Grant
- 2012-04-03 LT LTEP12712874.2T patent/LT2696889T/lt unknown
- 2012-04-03 ES ES12712874.2T patent/ES2656020T3/es active Active
- 2012-04-03 PL PL12712874T patent/PL2696889T3/pl unknown
- 2012-04-03 DK DK12712874.2T patent/DK2696889T3/en active
- 2012-04-03 BR BR112013026004-1A patent/BR112013026004B1/pt not_active IP Right Cessation
- 2012-04-03 KR KR1020137026366A patent/KR101554799B1/ko not_active Expired - Fee Related
- 2012-04-03 SG SG2013069554A patent/SG193483A1/en unknown
- 2012-04-03 SI SI201231134T patent/SI2696889T1/en unknown
- 2012-04-03 AU AU2012243178A patent/AU2012243178B2/en not_active Ceased
- 2012-04-03 PT PT127128742T patent/PT2696889T/pt unknown
- 2012-04-03 RS RS20171274A patent/RS56639B1/sr unknown
- 2012-04-03 ME MEP-2017-276A patent/ME02849B/me unknown
- 2012-04-03 HR HRP20171993TT patent/HRP20171993T1/hr unknown
-
2013
- 2013-08-22 IL IL228102A patent/IL228102A/en active IP Right Grant
- 2013-08-30 ZA ZA2013/06556A patent/ZA201306556B/en unknown
-
2018
- 2018-01-09 CY CY20181100021T patent/CY1119750T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262976A (en) | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof | |
| NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| WO2009033751A3 (en) | Use of leu-enkephalin as a therapeutic agent | |
| WO2009033782A3 (en) | Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis | |
| WO2009033783A3 (en) | Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis | |
| JP2016516016A5 (cg-RX-API-DMAC7.html) | ||
| WO2009039992A3 (en) | Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection | |
| JP2016505539A5 (cg-RX-API-DMAC7.html) | ||
| WO2009046863A3 (en) | Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent | |
| FI3482765T3 (fi) | Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi | |
| JP2014521684A5 (cg-RX-API-DMAC7.html) | ||
| WO2009040083A3 (en) | Use of a peptide as a therapeutic agent | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| WO2009033760A3 (en) | Use of fibronectin fragment (196-203 ) as a therapeutic agent | |
| WO2009039974A3 (en) | Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent | |
| JP2011225596A5 (cg-RX-API-DMAC7.html) | ||
| RU2014141514A (ru) | Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2011528333A5 (cg-RX-API-DMAC7.html) | ||
| NZ599930A (en) | Pharmaceutical compositions for the stimulation of stem cells. | |
| WO2009039968A3 (en) | Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection | |
| JP2014508734A5 (cg-RX-API-DMAC7.html) | ||
| NZ602693A (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| CN102643339A (zh) | 一种glp-1类似物、制备方法及其应用 |